Frontiers in Cardiovascular Medicine (Oct 2022)
The addition of genetic testing and cardiovascular magnetic resonance to routine clinical data for stratification of etiology in dilated cardiomyopathy
- Ravi J. Amin,
- Ravi J. Amin,
- Deborah Morris-Rosendahl,
- Deborah Morris-Rosendahl,
- Mat Edwards,
- Upasana Tayal,
- Upasana Tayal,
- Upasana Tayal,
- Rachel Buchan,
- Daniel J. Hammersley,
- Daniel J. Hammersley,
- Richard E. Jones,
- Richard E. Jones,
- Sabiha Gati,
- Sabiha Gati,
- Sabiha Gati,
- Zohya Khalique,
- Zohya Khalique,
- Zohya Khalique,
- Batool Almogheer,
- Batool Almogheer,
- Dudley J. Pennell,
- Dudley J. Pennell,
- Arun John Baksi,
- Arun John Baksi,
- Arun John Baksi,
- Antonis Pantazis,
- Antonis Pantazis,
- James S. Ware,
- James S. Ware,
- James S. Ware,
- Sanjay K. Prasad,
- Sanjay K. Prasad,
- Sanjay K. Prasad,
- Brian P. Halliday,
- Brian P. Halliday,
- Brian P. Halliday
Affiliations
- Ravi J. Amin
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Ravi J. Amin
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Deborah Morris-Rosendahl
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Deborah Morris-Rosendahl
- Clinical Genetics and Genomics Laboratory, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Mat Edwards
- Clinical Genetics and Genomics Laboratory, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Upasana Tayal
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Upasana Tayal
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Upasana Tayal
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Rachel Buchan
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Daniel J. Hammersley
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Daniel J. Hammersley
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Richard E. Jones
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Richard E. Jones
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Sabiha Gati
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Sabiha Gati
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Sabiha Gati
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Zohya Khalique
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Zohya Khalique
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Zohya Khalique
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Batool Almogheer
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Batool Almogheer
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Dudley J. Pennell
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Dudley J. Pennell
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Arun John Baksi
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Arun John Baksi
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Arun John Baksi
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Antonis Pantazis
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Antonis Pantazis
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- James S. Ware
- National Heart Lung Institute, Imperial College, London, United Kingdom
- James S. Ware
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- James S. Ware
- MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom
- Sanjay K. Prasad
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Sanjay K. Prasad
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Sanjay K. Prasad
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Brian P. Halliday
- Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- Brian P. Halliday
- National Heart Lung Institute, Imperial College, London, United Kingdom
- Brian P. Halliday
- Department of Inherited Cardiovascular Conditions, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- DOI
- https://doi.org/10.3389/fcvm.2022.1017119
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundGuidelines recommend genetic testing and cardiovascular magnetic resonance (CMR) for the investigation of dilated cardiomyopathy (DCM). However, the incremental value is unclear. We assessed the impact of these investigations in determining etiology.MethodsSixty consecutive patients referred with DCM and recruited to our hospital biobank were selected. Six independent experts determined the etiology of each phenotype in a step-wise manner based on (1) routine clinical data, (2) clinical and genetic data and (3) clinical, genetic and CMR data. They indicated their confidence (1-3) in the classification and any changes to management at each step.ResultsSix physicians adjudicated 60 cases. The addition of genetics and CMR resulted in 57 (15.8%) and 26 (7.2%) changes in the classification of etiology, including an increased number of genetic diagnoses and a reduction in idiopathic diagnoses. Diagnostic confidence improved at each step (p < 0.0005). The number of diagnoses made with low confidence reduced from 105 (29.2%) with routine clinical data to 71 (19.7%) following the addition of genetics and 37 (10.3%) with the addition of CMR. The addition of genetics and CMR led to 101 (28.1%) and 112 (31.1%) proposed changes to management, respectively. Interobserver variability showed moderate agreement with clinical data (κ = 0.44) which improved following the addition of genetics (κ = 0.65) and CMR (κ = 0.68).ConclusionWe demonstrate that genetics and CMR, frequently changed the classification of etiology in DCM, improved confidence and interobserver variability in determining the diagnosis and had an impact on proposed management.
Keywords
- dilated cardiomyopathy
- genetic testing
- cardiac magnetic resonance imaging
- etiology
- precision stratification